Biuletyn Informacyjny

Transkrypt

1 If we knew what it was we were doing, it would not be called research, would it? A. Einstein Centrum Onkologii Instytut im. Marii Skłodowskiej-Curie Oddział w Gliwicach Biuletyn Informacyjny Nr 85; Luty 2015 Biuletyn redaguje: Piotr Widłak (widlak@io.gliwice.pl; 9672) Sekretariat Naukowy Aleksander Sochanik (asochanik@io.gliwice.pl; 9677) Strona internetowa Centrum Badań Translacyjnych:

2 1. Zebrania naukowe Seminaria Działu Badawczego (czwartki, godzina 9.15, Sala Wykładowa im. J. Święckiego) Danuta Grabowska (Thomson Reuters. Intellectual Property & Science): Bibliometryczne spojrzenia na dorobek naukowy poprzez Web of Science Anna Habryka (CBT): Rola czynnika transkrypcyjnego HIF-1 w regulacji ekspresji ludzkiego genu HSPA2 Kliniczne Zebrania Naukowe (środy, godzina 8.15, Sala Konsyliarna Przychodni): Bogna Szcześniak-Kłusok (ZPN): Nowa klasyfikacja raka płuc Zakład Medycyny Nuklearnej i Endokrynologii Onkologicznej II Klinika Radioterapii i Chemioterapii Klinika Transplantacji Szpiku i Onkohematologii Marek Rusin (CBT): Znaczenie kliniczne cech metabolizmu komórki nowotworowej

3 2. Plan Naukowy 2014 Komisja ds. Odbioru Zadań Badawczych oceniła realizację zadań z Planu Naukowego na rok Poszczególnym zadaniom przyznano następującą punktację (w Gliwicach nie było zadań, których sprawozdanie odrzucono): Grupa tematyczna Praca wyróżniona (2+) Praca zrealizowana bez zastrzeżeń (2) Praca zrealizowana z zastrzeżeniami (1) I 1.A.1 1.A.2; 1.B.1; 1.B.2 II 2.C.1 2.A.1; 2.A.2 III 3.A.1; 3.A.2; 3.A.5 3.A.3; 3.A.4; 3.A.6; 3.A.7; 3.B.1; 3.B.2; 3.B.3; 3.B.4; 3.B.5; 3.B.7; 3.C.1; 3.C.2; 3.C.3; 3.C.4; 3.C.5; 3.D.1 3.B6. (wymagane zwiększenie badanej grupy chorych) IV 4.E.1 4.B1; 4.B.3; 4.B.4; 4.B.5; 4.B.6; 4.B.7; 4.C.1; 4.E.2; 4.E.3 Wyróżniono następujące zadania badawcze: 1.A.1. Analiza funkcjonowania szlaków sygnałowych zależnych od HSF1, NFkB i TP53 w odpowiedzi na stres indukowany w komórkach nowotworowych przez czynniki stosowane w terapii przeciwnowotworowej. M. Rusin, A. Abramowicz, D. Butkiewicz, M. Chorąży, A. Gdowicz-Kłosok, A. Gogler-Pigłowska, P. Janus, K. Klyszcz, Z. Krawczyk, M. Krześniak, I. Matuszczyk, J. Rogoliński, A. Rusin, K. Szołtysek, D. Ścieglińska, N. Vydra, P. Widłak, W. Widłak 2.C.1. Ocena genetycznych czynników ryzyka chorób tarczycy poszukiwanie wielogenowej redyspozycji do raka i zaburzeń czynnościowych metodami genomiki populacyjnej. D.Kula, D. Handkiewicz-Junak, Z. Puch, M. Kalemba, A. Kukulska, B. Jureck-Lubieniecka, J. Roskosz, A. Król, S. Szpak-Ulczok, E. Paliczka-Cieślik, T. Olczyk, A. Kropińska, B. Michalik, A. Koteck-Blicharz, A. Ledwoń, J. Krajewska, A. Syska-Bielak, M. Świerniak, T. Stokowy, E. Chmielik, A. Pawlaczek, M. Kowal, T. Tyszkiewicz, J. Żebracka-Gala, A. Pfeifer, A. Kluczewska-Gałka, R. Cyplińska, D. Rusinek, M. Kowalska, A. Chorąży 3.A.1. Walidacja i wdrożenie prognostyczno-predykcyjnych sygnatur molekularnych dla indywidualizacji i optymalizacji konformalnej radioterapii skojarzonej z chemioterapią u chorych na niedrobnokomórkowego raka płuca w stopniu zaawansowania IIIAN2 i IIIB. R. Suwiński, K. Galwas-Kliber, D. Butkiewicz, M. Pietrowska, M. Roś, M. Gliglok, G. Plewicki, U. Dworzecka, M. Kalinowska-Herok, M. Krześniak, I. Matuszczyk, A. Fiszer-Kierzkowska, A. Mazurek, U. Bojko, E. Małusecka, I. Domińczyk, M. Rusin, M. Gawkowska-Suwińska, A. Drosik, M. Jarząb, A. Idasiak, B. Jochymek, D. Syguła, B. Kłusek, R. Deja, J. Gliwińska, B. Masłyk, A. Zajusz, W. Widłak, M. Pelak, A. d'amico 3.A.2. Zbadanie wartości prognostycznej i predykcyjnej metylacji promotora genu MGMT, ekspresji integryny αvβ3 i receptora VEGFR1 i 2, obrazowania NMR oraz wielofazowego obrazowania PET ze specyficznymi znacznikami hipoksji i angiogenezy u chorych na glejaki wielopostaciowe po zastosowaniu pooperacyjnie radiochemoterapii. R. Tarnawski, E. Nowicka, B. Bobek-Billewicz, B. Lange, A. Stanek-Widera, A. Strączyńska-Niemiec, Ł. Zarudzki, G. Stasik-Pres, M. Samborska-Plewicka, A. Boratyn - Nowicka, A. Grządziel, L. Hawrylewicz, M. Stąpór-Fudzińska, M. Jarosz-Biej, T. Cichoń, R. Smolarczyk, S. Matuszczak, A. Hebda, D. Ścieglińska, A. Gogler-Pigłowska, S. Szala, J.Czapla, M. Jurkowski, G. Woźniak 3.A.5. Markery molekularne oraz metody obrazowania funkcjonalnego NMR jako narzędzia dla racjonalizacji wyboru schematu leczenia raka gruczołu krokowego. R. Suwiński, K. Behrendt, B. Masłyk, G. Plewicki, M. Giglok, T. Dworzecki, U. Dworzecka, B. Smolska-Ciszewska, K. Galwas, A. Idasiak, B. Białas, K. Lisowska, E. Małusecka, H. Urbańczyk, R. Deja, M. Latos, B. Bobek-Billewicz, B. Maciejewski, M. Wesołowski, D. Banaś, A. Stanek-Widera, B. Nikiel, R. Lamch, J. Młynarczyk-Liszka, A. Goraj-Zając, A. Kopeć, D. Lange 4.E.1. Opracowanie nowych terapii celowanych hamujących wzrost doświadczalnych nowotworów: wpływ kombinacji czynników antyangiogennych i immunostymulujących na wzrost doświadczalnych nowotworów u myszy. S. Szala, M. Jarosz-Biej, R. Smolarczyk, T. Cichoń, S. Matuszczak, J. Czapla, A. Szymańska - Żytecka, A. Zielińska.

4 3. Inne Informacje Lyon, France, 13 January The International Agency for Research on Cancer (IARC), the World Health Organization's specialized cancer agency, strongly disagrees with the conclusion of a scientific report on the causes of human cancer published in the journal Science on 2 January 2015 by Dr Cristian Tomasetti and Dr Bert Vogelstein.The study, which has received widespread media coverage, compares the number of lifetime stem cell divisions across a wide range of tissues with lifetime cancer risk and suggests that random mutations (or "bad luck") are "the major contributors to cancer overall, often more important than either hereditary or external environmental factors." For many cancers, the authors argue for a greater focus on the early detection of the disease rather than on prevention of its occurrence. If misinterpreted, this position could have serious negative consequences from both cancer research and public health perspectives. IARC experts point to a serious contradiction with the extensive body of epidemiological evidence as well as a number of methodological limitations and biases in the analysis presented in the report. "We already knew that for an individual to develop a certain cancer there is an element of chance, yet this has little to say about the level of cancer risk in a population," explains IARC Director Dr Christopher Wild. "Concluding that 'bad luck' is the major cause of cancer would be misleading and may detract from efforts to identify the causes of the disease and effectively prevent it." The past five decades of international epidemiological research have shown that most cancers that are frequent in one population are relatively rare in another and that these patterns vary over time. For example, oesophageal cancer is common among men in East Africa but rare in West Africa. Colorectal cancer, once rare in Japan, increased 4-fold in incidence in just two decades. These observations are characteristic of many common cancers and are consistent with a major contribution of environmental and lifestyle exposures, as opposed to genetic variation or chance ("bad luck"). Furthermore, IARC experts identify several limitations in the report itself. These include the emphasis on very rare cancers (e.g. osteosarcoma, medulloblastoma) that together make only a small contribution to the total cancer burden. The report also excludes, because of the lack of data, common cancers for which incidence differs substantially between populations and over time. The latter category includes some of the most frequent cancers worldwide, for example those of the stomach, cervix, and breast, each known to be associated with infections or lifestyle and environmental factors. Moreover, the study focuses exclusively on the United States population as a measure of lifetime risk. The comparison of different populations would have yielded different results. Although it has long been clear that the number of cell divisions increases the risk of mutation and, therefore, of cancer, a majority of the most common cancers occurring worldwide are strongly related to environmental and lifestyle exposures. In principle, therefore, these cancers are preventable; based on current knowledge, nearly half of all cancer cases worldwide can be prevented. This is supported in practice by rigorous scientific evidence showing decreases in cancer incidence after preventive interventions. Notable examples include drops in rates of lung cancer and other tobacco-related cancers after reductions in smoking and declines in hepatocellular carcinoma rates among people vaccinated against hepatitis B virus. "The remaining knowledge gaps on cancer etiology should not be simply ascribed to 'bad luck'," says Dr Wild. "The search for causes must continue while also investing in prevention measures for those cancers where risk factors are known. This is particularly important in the most deprived areas of the world, which face a growing burden of cancer with limited health service resources." W dniach 8 i 9 maja 2015, w Instytucie Fizyki Jądrowej PAN w Krakowie, odbędzie się konferencja 2 nd Central European Symposium on Radiation Oncology: Technological and Biological Sunrise for Radiation Oncology, której współorganizatorem jest Instytut. Program konferencji w załączeniu. Zgłoszenia doniesień plakatowych można składać do 28 lutego Opłata wpisowa (pokrywa koszt materiałów konferencyjnych, wyżywienia i transportu z/do centrum Krakowa) wynosi 300 PLN oraz 150 PLN w przypadku studentów i doktorantów (przy rejestracji do 31 marca 2015). Więcej informacji na stronie Konferencja "Rak Tarczycy i inne nowotwory złośliwe wewnętrznego wydzielania" odbędzie się listopada 2015 r. w Wiśle.

5 2nd Central European Symposium on Radiation Oncology Technological and Biological Sunrise for Radiation Oncology May 8-9th, 2015, Poland, Kraków Preliminary Programme 8th May 2015 (Friday) 8:00-8:30 Installation of posters, registration 8:30-8:40 Opening of the Symposium M. Jeżabek (IFJ PAN, Poland) J. Jakubowicz (Institute of Oncology, Kraków, Poland) M. Reinfuss (Institute of Oncology, Kraków, Poland) 8:40-10:30 Session 1 New Concepts and Technologies Repair of charged-particle induced DNA double-strand breaks in mammalian cells D. Chen (UT Southwestern Medical Center, USA) Translational research in particle therapy M. Durante (GSI Helmholtz Centre for Heavy Ion Research, Darmstadt, Germany) NCI Support for Particle Therapy J. Capala (National Cancer Institute, USA) Can biomarkers modify clinical practice of radiation therapy? K. Składowski (Institute of Oncology, Gliwice, Poland) HPV-related oropharyngeal cancer - opportunity for less aggressive treatment? A. Kawecki (Institute of Oncology, Warsaw, Poland) 10:30-11:00 Coffee break 11:00-13:00 Session 2 Proton and Ion Therapy Utilizing proton biological effect variations in intensity-modulated proton therapy H. Paganetti (Harvard Medical School, USA) To be announced J. L. Habrand (Centre François Baclesse, France) Indications for proton therapy in Poland: Consensus Report of National Consultant for Radiation Oncology R. Dziadziuszko (Medical University of Gdańsk, Poland) More than "gold standard" of proton radiotherapy - fail or hope? B. Sas-Korczyńska (Institute of Oncology, Kraków, Poland) Results of proton beam therapy in uveal melanoma B. Romanowska-Dixon (University Hospital of Kraków, Poland) Proton therapy and research at the Bronowice Cyclotron Centre IFJ PAN P. Olko (IFJ PAN, Poland) 13:00-14:00 Lunch 14:00-16:15 Session 3 Prognostic and Predictive Markers for Radiotherapy Radiogenomics to predict risk of radiotherapy toxicity C. West (Christie Hospital NHS Foundation Trust, UK) The Continuing Development of Predictive Assays in Radiotherapy G. Wilson (Beaumont Hospital, USA) The importance of the tumor microenvironment for radiotherapy J. Bussink (Radboud University, The Netherlands) Exosomes potential vehicle for communication between irradiated cells P. Widłak (Institute of Oncology, Gliwice, Poland) Prognostic significance of clinical and biological tumour features in rectal cancer patients receiving short-course preoperative radiotherapy A. Gasińska (Institute of Oncology, Kraków, Poland) Changes in expression of selected markers between primary breast cancer and its synchronous lymph node metastases J. Niemiec (Institute of Oncology, Kraków, Poland) 16:45-18:15 Session 4 New Concepts and Technologies Radiomics: extracting more clinical and biological information from standard imaging P. Lambin (Universiteit Maastricht, The Netherlands) Late side effects after the second irradiation of children R. Mayer (EBG MedAustron, Austria) Protons or photons in radiation therapy for the prostate cancer J. Fijuth (Regional Cancer Center, Łódź, Poland) Split-course accelerated, hyperfractionated irradiation (CHA-CHA) for advanced head and neck cancer patients -results of clinical trial L. Miszczyk (Institute of Oncology, Gliwice, Poland) 20:00 - Conference dinner 9th May 2015 (Saturday) 8:30-10:30 Session 5 Medical Physics and Information Technology Future Plan of a Heavy Ion Radiation Therapy and Research Facility in Dallas, Texas A. Pompos (UT Southwestern Medical Center, USA) Advantages of scanning beam for proton radiotherapy H. Nystrom (The Skandion Clinic, Sweden) Undesired doses outside the treatment field in conventional and proton radiotherapy L. Stolarczyk (IFJ PAN, Poland) Towards the first patient. From acceptance tests to commissioning of a PBS dedicated gantry T. Kajdrowicz (IFJ PAN, Poland) A new optical positioning and tracking system for radiation therapy P. Kukołowicz (Institute of Oncology, Warsaw, Poland) Challenges in the development of an ocular proton radiotherapy facility J. Swakoń (IFJ PAN, Poland) 10:30-11:00 Coffee break 11:00-14:00 Session 6 Radiotherapy in Combined Treatment Modalities Radiosurgery for functional disorder, state of art. M. Marchetti (Istituto Neurologico Carlo Besta, Italy) Is concurrent chemoradiotherapy the gold standard to-day for stage III NSCLS? P. van Houtte (University of Brussels, Belgium) mirna as potential biomarkers of therapeutic response in head and neck cancer M. Story (UT Southwestern Medical Center, USA) Neurocognitive Aspects on Craniospinal Irradiation with Protons in Pediatric Patients T. Björk-Eriksson (Sahlgrenska University Hospital, Sweden) Clinical and biological rationale for hyperfractionated preoperative radiotherapy in rectal cancer R. Suwiński (Institute of Oncology, Gliwice, Poland) Automatic glioblastoma detection for radiotherapy planning using Gaussian mixture model based segmentation of the MRI apparent diffusion coefficient maps R. Tarnawski (Institute of Oncology, Gliwice, Poland) Chordomas - old challenges, new opportunities A. Napieralska (Institute of Oncology, Gliwice, Poland) Combined local treatment in adults with intraocular tumours A. Markiewicz (University Hospital of Kraków, Poland) 14:00-15:00 Lunch 16:15-16:45 Coffee break 15:00-16:00 Visit to the proton therapy centre